P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 226.83 INR 2.5% Market Closed
Market Cap: 299.5B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+34%
Revenue
Forecast
+2%
Operating Income
Forecast
+7%
Net Income
Forecast
+23%

Wall Street
Price Targets

PPLPHARMA Price Targets Summary
Piramal Pharma Ltd

Wall Street analysts forecast PPLPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PPLPHARMA is 308.55 INR with a low forecast of 267.65 INR and a high forecast of 357 INR.

PPLPHARMA Lowest Forecast
Wall Street Target
267.65 INR
18% Upside
PPLPHARMA Average Forecast
Wall Street Target
308.55 INR
36% Upside
PPLPHARMA Highest Forecast
Wall Street Target
357 INR
57% Upside
Lowest
Price Target
267.65 INR
18% Upside
Average
Price Target
308.55 INR
36% Upside
Highest
Price Target
357 INR
57% Upside
Piramal Pharma Ltd Competitors:
Price Targets
G
GLS
Glenmark Life Sciences Ltd
10% Upside
LABB
Genomma Lab Internacional SAB de CV
7% Upside
APLLTD
Alembic Pharmaceuticals Ltd
15% Upside
000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
33% Upside
G
GLS
Glenmark Life Sciences Ltd
10% Upside
LABB
Genomma Lab Internacional SAB de CV
7% Upside
APLLTD
Alembic Pharmaceuticals Ltd
15% Upside
000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
33% Upside

Revenue
Forecast

Revenue Estimate
Piramal Pharma Ltd

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's revenue is 62%. The projected CAGR for the next 3 years is 14%.

62%
Past Growth
14%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Piramal Pharma Ltd

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's operating income is 24%. The projected CAGR for the next 3 years is -2%.

24%
Past Growth
-2%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Piramal Pharma Ltd

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's net income is -77%. The projected CAGR for the next 3 years is 260%.

-77%
Past Growth
260%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
PPLPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
PPLPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PPLPHARMA stock valuation using valuation multiples.
Wall Street Estimates
PPLPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PPLPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PPLPHARMA's stock price target?
Price Target
308.55 INR

According to Wall Street analysts, the average 1-year price target for PPLPHARMA is 308.55 INR with a low forecast of 267.65 INR and a high forecast of 357 INR.

What is Piramal Pharma Ltd's Revenue forecast?
Projected CAGR
14%

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's revenue is 62%. The projected CAGR for the next 3 years is 14%.

What is Piramal Pharma Ltd's Operating Income forecast?
Projected CAGR
-2%

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's operating income is 24%. The projected CAGR for the next 3 years is -2%.

What is Piramal Pharma Ltd's Net Income forecast?
Projected CAGR
260%

For the last 2 years the compound annual growth rate for Piramal Pharma Ltd's net income is -77%. The projected CAGR for the next 3 years is 260%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.